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Background:  Macroprolactin  is  a  molecule  that  results  from  association  between  monomeric  prolactin
(PRL)  and  immunoglobulin  G  (IgG).  It has longer  half-life  and  is considered  biologically  inactive,  although
it  retains  immunoreactivity,  being  detected  in  most  available  immunoassays.
Objective:  To  evaluate  polyethylene  glycol  (PEG)  precipitation  method  in  routine  detection  of  macropro-
lactin.
Methods:  During  4 months  a  prospective  study  was  performed  in  our  hospital.  Serum  samples  of
PRL  ≥  30  ng/ml  were  collected  and  pre-treated  with  PEG.  Initial  PRL  and  post-PEG  PRL  (in  the  super-
natant)  were  detected  by electrochemiluminescence  – Cobas  e170®. Samples  were  classiﬁed  as  having  a
predominance  of macroprolactin  if recovery  rate (RR)  of  PRL was  <40%  and  an  indeterminate  result  for
the  predominance  of macroprolactin  if RR  was  40–65%.
Results:  Ninety-six  samples  were  enrolled,  with  median  PRL  56.1  ng/ml  (30.7–3667).  PEG precipitation
produced  a decrease  in  PRL  values  in  all of  the  cases  (mean  reduction  of 22%).  Two  cases  of macroprolactin
predominance  were  detected  (RR  4.9%  and  16.1%)  and  2 cases  were  indeterminate  (RR  45.1%  and  63.7%).
Discussion:  PEG  precipitation  method  is a simple  and  low-cost  laboratory  technique  that  can  be rou-
tinely  used  in  clinical  practice.  Macroprolactin  accounting  for hyperprolactinemia  is a common  cause
of  misdiagnosis.  Screening  for  macroprolactin  in  hyperprolactinemic  patients  may  avoid  unnecessary
investigation  and  inappropriate  treatment.
© 2013  Sociedade  Por-
tuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
Avaliac¸ ão  de  macroprolactina  pelo  método  de  precipitac¸ ão  com
polietilenoglicol
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Introduc¸ ão:  A  macroprolactina  é uma  molécula  que  resulta  da associac¸ ão  entre  a prolactina  (PRL)
monomérica  e a  imunoglobulina  G  (IgG).  Tem  uma semi-vida  superior  e é considerada  biologicamente
inactive,  apesar  de ter imunorreactividade  e ser  detectada  pela  maior  parte  dos  imunoensaios  laborato-
riais actualmente  utilizados.
Objectivo:  Avaliar  o método  de  precipitac¸ ão com  polietilenoglicol  (PEG)  na  avaliac¸ ão  laboratorial  da
macroprolactina.
Métodos:  Foi  elaborado  no nosso  hospital  um  estudo  prospectivo  com  4 meses  de  durac¸ ão.  Foram  colhidas
e  pré-tratadas  com  PEG  amostras  de  PRL  sérica  ≥  30  ng/ml.  Os  valores  de  PRL  inicial  e de  PRL pós-PEG
(no  sobrenadante)  foram  obtidos  por  electroquimioluminescência  –  Cobas  e170®. As amostras  foram
classiﬁcadas  como  tendo  predomínio  de  macroprolactina  se  a  taxa  de recuperac¸ ão  (RR)  da  PRL  fosse
<40%  e como  tendo  um  resultado  indeterminado  se a RR  estivesse  entre  40 e  65%.
Resultados:  Noventa  e seis  amostras  foram  analisadas,  com  PRL mediana  de  56.1 ng/ml  (30.7–3667).  A
precipitac¸ ão com  PEG  resultou  numa  diminuic¸ ão  no valour  da  PRL  em  todos  os  casos  (reduc¸ ão  média
de  22%).  Foram  detectados  2 casos  de  predomínio  de  macroprolactina  (RR 4.9%  e 16.1%) e 2  casos  com
resultado  indeterminado  (RR 45.1%  e 63.7%).
∗ Corresponding author.
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Discussão:  A  precipitac¸ ão com  PEG  é um  método  laboratorial  simples  e barato  que  pode  ser utilizado  por
rotina  na  prática  clínica.  A  macroprolactina  é uma  causa  relativamente  frequente  de  hiperprolactinemia
que, quando  detectada,  pode  permitir  evitar  custos  adicionais  com  exames  radiológicos  ou  tratamentos
inapropriados.
©  2013 Sociedade  Portuguesa  de Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
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Prolactin (PRL) is a hormone produced by lactotroph cells in
nterior pituitary gland and its action is essential for human species
urvival. The main functions of PRL are exerted during pregnancy,
nabling breast development, milk production and lactation. It has
lso reproductive and metabolic effects, like stimulation of immune
esponse. PRL receptors are, therefore, expressed in several tissues,
ike breast, pituitary, adrenal cortex, prostate, gonads, liver and
ther essential ones.1
The PRL molecule presents great heterogeneity with respect to
olecular mass. Most human circulating PRL (about 85–95%) exist
n a monomeric form of 23 kDa but high molecular mass isoforms
ncluding big-PRL, a dimer of 50 kDa and big–big-PRL or macro-
rolactin, a variant of 150–170 kDa, may  also be present. These
igh-molecular weight forms have been described either in healthy
ubjects or in hyperprolactinemic patients.
Hyperprolactinemia refers to a state of elevated serum lev-
ls of PRL and may  be caused, among others, by a prolactinoma,
n autonomous PRL secreting pituitary adenoma, or by a loss of
nhibitory effect of dopamine by other kinds of pituitary or sellar
umours. In some situations, however, no cause for elevated levels
f PRL can be identiﬁed and patients are assumed to have idiopathic
yperprolactinemia.1
Macroprolactinemia is another source of hyperprolactinemia.
t accounts for a variable amount of all reported cases of hyper-
rolactinemia (10–46%), depending on the immunoassay used for
aboratory determination.2–5
Macroprolactin is most frequently a complex formed by
 monomeric PRL and an immunoglobulin G molecule but
ost-translational modiﬁcation of pituitary PRL with vary-
ng glycosylation and phosphorylation degrees have also been
escribed.6,7
This tertiary structure modiﬁcation of PRL, responsible for reten-
ion in vascular tree and reduced tissue availability, contributes to
ts clinical inactivity. However, as the PRL part of PRL–IgG complex
till preserves immunoreactivity in most available immunoassays
sed nowadays and as it has lower clearance rate and augmented
alf-life, it may  cause high PRL levels in routine tests.
Sometimes, most of the circulating PRL may  be in the macropro-
actin form, leading, in those circumstances, hyperprolactinemia to
e called macroprolactinemia.
The gold standard test to determine the presence of macropro-
actinemia is gel ﬁltration chromatography, but more available and
ess expensive alternatives have been described, like precipitation
ith polyethylene glycol (PEG).8
The aim of this study was to evaluate PEG precipitation method
n routine detection of macroprolactin in a central hospital.
aterials and methods
Starting in August 2012, a 4-month prospective study was
erformed in our hospital, which consisted on collecting serum
amples with high PRL levels (PRL ≥ 30 ng/ml; reference range: ♀
.79–23.3 ng/ml and ♂ 4.04–15.2 ng/ml) from individuals indepen-
ently of their sex, diagnosis or treatment till then. Twenty-ﬁveEspaña,  S.L.  Todos  os  direitos  reservados.
grams of PEG 6000 (Merck® ref. 807491) was dissolved in 60 ml
of distilled water at room temperature (18–25 ◦C) and mixed at
vortex, with volume fulﬁlled till 100 ml  of solution. Two hun-
dred and ﬁfty microliters of that 25% PEG solution were added
at room temperature (20–25 ◦C) to equal volume of patients’ sera.
After thorough vortex mixing and 30 min  stabilization, the solu-
tion was centrifuged at 9500 × g for 10 min. Initial-PRL (pre-PEG)
and supernatant-PRL (post-PEG) were detected by electrochemilu-
minescence – Cobas e170®. PRL recovery rate (RR) was determined
by the ratio: supernatant-PRL/initial-PRL × 100, after correction of
post-PEG PRL result for PEG dilution factor of 2. Samples were
classiﬁed as having a predominant macroprolactin form if RR of
PRL was  <40%. RR > 65% indicated monomeric PRL predominance
and RR 40–65% was  were classiﬁed as indeterminate. Positive con-
trol for macroprolactin (RR 37%) was  obtained by UK NEQAS® –
the United Kingdom National External Quality Assurance Scheme,
sample G970.
Results
Among a total of 678 samples of PRL analyzed in our lab-
oratory over 4 months of study, 96 consecutive samples of
PRL ≥ 30 ng/ml were identiﬁed (14.2%), with median initial-PRL
56.1 ng/ml (30.7–3667) and median post-PEG PRL 43.1 ng/ml
(2–2966).
Two cases of macroprolactin predominance (2.1%) were
detected in this study, with RR of 4.9% (pre-PEG/post-PEG prolactin
40.8/2.0 ng/ml, respectively) and RR of 16.1% (pre-PEG/post-
PEG prolactin 57.4/9.26 ng/ml, respectively). Two cases were
indeterminate, with RR of 45.1% (pre-PEG/post-PEG prolactin
37.96/17.12 ng/ml, respectively) and RR of 63.7% (pre-PEG/post-
PEG prolactin 33.2/21.16 ng/ml, respectively). The remaining 92
cases showed RR between 69.1% and 93.5%.
After initial results, a second analysis was  performed in two
patients who  were able to cooperate (one case of positive result and
one case indeterminate). Second/ﬁrst RR were similar: 15.6/16.1%
and 41.6/45.1%, respectively).
Treatment with PEG produced a decrease in PRL values in all
sera, with mean reduction of 22% (or 20% considering only the 92
cases of monomeric PRL predominance).
Macroprolactin positive cases are now being reviewed by their
endocrinologists and a brief description is made as follows:
Case 1
Female, aged 40 years, sent to the endocrinology department
because of mild galactorrhea and persistent hyperprolactinemia
(PRL 142 ng/ml, reference range 4.79–23.3), but with regular
menses and no infertility background. Sellar magnetic resonance
imaging (MRI) showed an irregular area of 4 mm,  with contrast
enhancement, probably a pituitary microadenoma, according to
previous clinical information of hyperprolactinemia. She started
on dopamine agonist (DA) treatment with prolactinemia reduc-
tion but it never normalized (PRL 40.6 ng/ml under 5 mg  of
bromocriptine). After PEG precipitation, ﬁnal PRL was 2 ng/ml (RR
4.9%).
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ase 2
Female, aged 38 years, being followed in the endocrinol-
gy department for the last 18 years because of obesity (BMI
0.3 kg/m2) and irregular menses. She had no galactorrhea. PRL was
55.2 ng/ml (reference range 4.79–23.3) but no abnormal lesion
as seen in the pituitary imaging study. She started on bromocrip-
ine with PRL normalization but oligomenorrhea persisted and
yperprolactinemia recurred after DA withdrawal (PRL 57.4 ng/ml).
o signiﬁcant weight reduction was seen during follow-up time.
fter PEG precipitation, ﬁnal PRL was 9.3 ng/ml (RR 16.1%).
The case of indeterminate result that was conﬁrmed as inconclu-
ive in this study referred to a 32-year-old female patient observed
n the endocrinology department because of mild hyperprolactine-
ia, conﬁrmed in subsequent analysis (PRL 37.93 ng/ml). She had
ligomenorrhea but no galactorrhea and no abnormal images in
erebral computorized tomography (CT). She was diagnosed with
utoimmune thyroiditis with subclinical hypothyroidism and is
ow medicated with levothyroxine 75 g/day but in the last year
he had some irregular menses, PRL 37.98 ng/ml and borderline TSH
esults (TSH 3.9–6.2 UI/ml, reference range 0.27–4.2 UI/ml).
iscussion and conclusions
Macroprolactin is a high-molecular weight molecule that was
rst described in 1981 by Wittaker et al.9 It is a PRL-IgG
mmunocomplex in which endogenous IgG molecule is directed
gainst epitopes on N- and C-terminal residues of monomeric
RL.10
The likelihood that current immunoassays will detect macro-
rolactin depends on the previous binding of PRL to endogenous
mmunoglobin and the availability of PRL epitopes to bind the
ssays’ antibody. Whenever the assay’s antibody binds an avail-
ble epitope in PRL molecule, it is accounted as monomeric PRL
nd contributes to total PRL levels. That is what determines the
mmunoassay’s sensitivity to differentiate monomeric PRL from
acroprolactin.
Treatment of sera with high concentrations of PEG may over-
ome this problem. PEG precipitates out high-molecular weight
ompounds including immunoglobulin. As it can precipitate
acroprolactin, leaving reduced levels in the supernatant, it has
een applied to assess cases of elevated PRL due to macropro-
actin predominance. This method is cheap, reproducible and easily
erformed and it seems the one that most tightly correlates with
oncentrations measured by gel ﬁltration chromatography (GFC),
he gold standard for macroprolactin assessment.4,11 GFC is not fea-
ible to use in routine laboratory practice as it is too expensive and
echnically demanding.4
Monomeric PRL may  also precipitate during technical
rocessing with PEG, reducing post-PEG PRL values in all serum
amples.4 This lack of speciﬁcity, responsible for 5–44% reduc-
ion in ﬁnal PRL even in normoprolactinemic sera,12 was also
emonstrated in the present study, with mean 20% reduction in
ll 92 cases of monomeric PRL predominance. To minimize this
ap, new reference intervals for PRL could be obtained after PEG
recipitation of PRL in normoprolactinemic individuals’ sera12
r new calibration curves could be obtained after treating assay
alibrators by the same PEG procedure.13
In the present study, we used the classic approach of macropro-
actin assessment by PEG precipitation, establishing a particular
ut-off for RR of PRL.14 Some authors have taken into account the
acroprolactin-speciﬁc RR that was achieved after PEG precipi-
ation of positive macroprolactin samples in GFC,15,16 others use
R previously validated, like in the present study. Most frequently,
esults of RR <30%14 or RR <40%5,17,18 have been published. In thisiabetes Metab. 2014;9(1):25–28 27
study, RR <40% was  considered positive for macroprolactinemia,
as it seemed the more reliable and agreed criterion. More variety
has been described in literature in what concerns to the interval
for indeterminate presence of macroprolactin, although the upper
limit of that interval seems frequently an arbitrary option. Consen-
sually, indeterminate results would imply GFC conﬁrmation.
Some situations of hyperprolactinemia can represent simulta-
neous macroprolactinemia and elevated pituitary PRL secretion
(because ﬁnal PRL result, even if macroprolactinemia is present,
may  still be above the upper limit of normal).19 These cases imply
the same clinical approach than isolated true hyperprolactinemia,
in order to diagnose organic lesion responsible for it.
The incidence of macroprolactinemia depends on the nature of
the study centre, as some receive samples of elevated prolactinemia
for macroprolactin conﬁrmation. In the present study, macropro-
lactinemia was  present in a lower rate than usually reported (2.1%
vs 10–46%).5,11,18,20-22 The fact that all hyperprolactinemic samples
were collected independently of DA treatment or the presence of
pituitary macroadenomas may  have contributed to it.
Bioactivity of macroprolactin molecule has been questioned but
it is still a confusing area of discussion. Its high molecular mass
conﬁnes it to the intravascular space probably limiting its bioavail-
ability and biological activity but intermittent dissociation of
macroprolactin from IgG molecule has been suggested.23 Although
macroprolactinemic patients may  have symptoms similar to those
with true hyperprolactinemia, as symptoms are themselves the
motive for serum PRL evaluation, they are sometimes nonspeciﬁc
and are also seen in general population. Galactorrhea, irregular
menses, headache or infertility have been identiﬁed in macro-
prolactinemic and true hyperprolactinemic subjects but seems
signiﬁcantly less common in the former group.5,12,24 Clinical
features alone may  not reliably distinguish macroprolactinemic
patients from patients with true hyperprolactinemia.
Sellar imaging studies are frequently performed in patients with
retrospectively identiﬁed macroprolactinemia. Pituitary microade-
nomas have been described in this population but its true clinical
relevance is unclear, as pituitary incidentalomas are also found in
about 10–20% of the general population at autopsy.2,5,12
The beneﬁcial effect of DA in macroprolactinemic patients has
been described and seems more evident for patients with asso-
ciated galactorrhea12,25; although spontaneous improvement of
symptoms may  also occur in those patients.24
In conclusion, macroprolactinemia is a misdiagnosed cause of
hyperprolactinemia. Its identiﬁcation may  lead clinicians to recon-
sider the likelihood of requesting sophisticated and expensive
imaging studies, even in apparently symptomatic patients.
Applying PEG precipitation to hyperprolactinemic sera is an easy
and reliable method of screening for macroprolactin that we  vali-
dated in our institution.
In the present study, we validated this technique and found two
cases of macroprolactinemia predominance, with RR of 4.9% and
16.1% and two cases of indeterminate results, needing GFC conﬁr-
mation.
We understand that screening for macroprolactinemia may be
very important in daily clinical practice, especially in clarifying per-
sistent hyperprolactinemia in apparently healthy individuals. Being
so, in our hospital we  are now able to measure macroprolactin by
PEG precipitation whenever appropriate, preferentially before any
investigation or pharmacologic therapy is initiated.Protection of human and animal subjects. The authors declare
that no experiments were performed on humans or animals for
this study.
2 inol D
C
l
p
s
p
R
n
C
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
28 A.M. Silva et al. / Rev Port Endocr
onﬁdentiality of data. The authors declare that they have fol-
owed the protocols of their work centre on the publication of
atient data and that all the patients included in the study received
ufﬁcient information and gave their written informed consent to
articipate in the study.
ight to privacy and informed consent. The authors declare that
o patient data appear in this article.
onﬂicts of interest
The authors have no conﬂicts of interest to declare.
eferences
1. Kronenberg HM,  Melmed S, Polonsky KS, Larsen PR. Anterior pituitary. In:
Williams textbook of endocrinology. Canada: Saunders Elsevier; 2008. p.
155–261.
2. Gibney J, Smith T, McKenna TJ. Clinical relevance of macroprolactin. Clin
Endocrinol (Oxf). 2005;62:633–43.
3. Amadori P, Dilberis C, Marcolla A. All the studies on hyperprolactinemia should
not  forget to consider the possible presence of macroprolactinemia. Eur J
Endocrinol. 2004;150:93–4.
4. Kavanagh L, McKenna TJ, Fahie-Wilson M,  Gibney J, Smith TP. Speciﬁcity and
clinical utility of methods for the detection of macroprolactinemia. Clin Chem.
2006;52:1366–72.
5. Leslie H, Courtney CH, Bell PM,  Hadden DR, McCance DR, Ellis PK, et al. Labora-
tory and clinical experience in 55 patients with macroprolactinemia identiﬁed
by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab.
2001;86:2743–6.
6. Hattori N. The frequency of macroprolactinemia in pregnant women and the
heterogeneity of its aetiology. J Clin Endocrinol Metab. 1996;81:586–90.
7. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and
regulation of secretion. Physiol Rev. 2000;80:1523–631.
8. Fahie-Wilson MN,  Soule SG, Macroprolactinaemia:. contribution to hyperpro-
lactinemia in a district general hospital and evaluation of a screening test based
on  precipitation with polyethylene glycol. Ann Clin Biochem. 1997;34:252–8.9. Wittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperpro-
lactinemia due to big, big prolactin. J Clin Endocinol Metab. 1981;53(4):863–6.
0. Hattori N, Nakayama Y, Kitagawa K, et al. Anti-prolactin (PRL) autoantibody-
binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol.
2006;190(2):287–93.
2iabetes Metab. 2014;9(1):25–28
1. Smith TP, Suliman AM,  Fahie-Wilson MN,  McKenna TJ. Gross variability in the
detection of prolactin in sera containing big–big prolactin (macroprolactin) by
commercial immunoassays. J Clin Endocrinol Metab. 2002;87:5410–5.
2. Suliman AM,  Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and
mismanagement of hyperprolactinemic patients before the introduction of
macroprolactin screening: application of a new strict laboratory deﬁnition of
macroprolactinemia. Clin Chem. 2003;49(9):1504–9.
3. Li W,  Sustarsic D, Fahie-Wilson M,  Vankrieken L, Walker K, Del Rosario I, et al.
Matrix effect of PEG precipitation in detection of Macroprolactin in Immulite®
and Immulite® 2000 Prolactin assays, Scientiﬁc Poster No. B-75. In: AACC Annual
Meeting. 2002.
4. Veloza A, Prazeres S. Prolactina e o laboratório. Acta Med  Port.
2011;24(S4):1029–34.
5. Vieira JGH, Tachibana TT, Obara LH, Maciel RMB. Extensive experience and
validation of polyethylene glycol precipitation as a screening method for macro-
prolactinemia. Clin Chem. 1998;44(8):1758–9.
6. Fahie-Wilson MN.  Polyethylene glycol precipitation as a screening method for
macroprolactinemia. Clin Chem 1999;45:436–7.
7. Beltran L, Fahie-Wilson M,  McKenna TJ, Kavanagh L, Smith TP. Serum total pro-
lactin and monomeric prolactin reference intervals determined by precipitation
with polyethylene glycol: evaluation and validation on common immunoassays
platforms. Clin Chem. 2008;54:1673–81.
8. Olukoga AO, Kane JW.  Macroprolactinemia validation and application of the
polyethylene glycol precipitation test and clinical characterization of the con-
dition. Clin Endocrinol. 1999;51:119–26.
9. Glezer A, D’Alva CB, Bronstein MD,  Vieira JGH. Macroprolactina e incidentaloma
hipoﬁsário. Arq Bras Endocrinol Metabol. 2002;46:45–50.
0. Valette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al.
Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab.
2002;87:581–8.
1. Sanchez-Eixeres MR,  Mauri M,  Alfayate R, Graells ML,  Miralles C, Lopez A,
et  al. Prevalence of macroprolactin detected by Elecsys 2010. Horm Res.
2001;56:87–92.
2. Vieira JGH, Tachibana TT, Ferrer CM,  Sá J, Biscolla RP, Hoff AO, et al. Hyperpro-
lactinemia: new assay more speciﬁc for the monomeric form does not eliminate
screening for macroprolactin with polyethylene glycol precipitation. Arq Bras
Endocrinol Metab. 2010;54/9:856–7.
3. Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic
hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G
complex. J Clin Endocrinol Metab. 1997;82:3107–10.
4. Lu C-C, Hsieh C-J. The importance of measuring macroprolactin in the differ-
ential diagnosis of hyperprolactinemic patients. Kaohsiung J Med Sci. 2012;28:
94–9.
5. Padilla SL, Person GK, McDonough PG, Reindollar RH. The efﬁcacy of
bromocriptine in patients with ovulatory dysfunction and normoprolactinemic
galactorrhea. Fertil Steril. 1986;46:1026–31.
